CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation
PHILADELPHIA, July 30, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR).
On July 27, 2026, the U.S. Food and Drug Administration (“FDA”) released briefing materials concerning Capricor’s application for FDA approval of deramiocel, an investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.
According to Reuters, “FDA staff reviewers raised concerns about the effectiveness data for Capricor Therapeutics’ cell therapy for a heart condition related to Duchenne muscular dystrophy . . ..” Reuters reported that “[t]he agency’s staff said Capricor changed how it measured the main results after the therapy’s late-stage trial ended, calculating arm-function performance as a percentage change instead of the original plan of analyzing scores in a 42-point test.”
On July 29, 2026, Stocktwits (via Yahoo Finance) reported that "[s]hares of Capricor . . . are on track for a record weekly selloff after an [FDA] advisory panel voted 9-3 against Deramiocel . . .."
Stocktwits further reported that "[t]he FDA's Cellular, Tissue, and Gene Therapies Advisory Committee concluded on Wednesday that Capricor had not shown substantial evidence that Deramiocel effectively treats cardiomyopathy in DMD. Several panelists said the data was not convincing enough."
On this news, shares of Capricor stock declined approximately 67%, closing at $6.57 per share on July 29, 2026. In premarket trading on July 30, 2026, the price of Capricor stock fell another 50% to approximately $3.00 per share.
Capricor investors who have suffered financial losses are encouraged to complete Kehoe Law Firm's Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, myarnoff@kehoelawfirm.com, info@kehoelawfirm.com, for additional information and a free, no-obligation evaluation of potential legal claims.
ABOUT KEHOE LAW FIRM, P.C.
Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.
Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.
This press release may constitute attorney advertising.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
